London, United Kingdom
10.10.16 - 11.10.16
Since 10 years of EU paediatric regulation, considerable progress has been made by all involved in paediatric research: companies, regulators, academia, healthcare professionals and patients. Many products have now obtained a paediatric indication and new data are produced on a daily basis. Nevertheless, many trials recruit slowly and drug development plans are not completed.
The aim of this conference is to discuss how drug development can be further optimised to the benefit of children’s health. This will include a discussion on what we have learned during these years of full operation of the EU paediatric regulation, new concepts and strategies for an integrated approach at each and every step of paediatric development.
To register, click here.
For more information about the programme, click here.
The aim of this conference is to discuss how drug development can be further optimised to the benefit of children’s health. This will include a discussion on what we have learned during these years of full operation of the EU paediatric regulation, new concepts and strategies for an integrated approach at each and every step of paediatric development.
To register, click here.
For more information about the programme, click here.